Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

The Role of Wnt‐10b in Osteoblast Development
Chase, J. , Moedder, Ulrike, Chase, Jennifer A, Monroe, David G. , Khosla, Sundeep

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.888.1 Get It

Wnt signaling plays a central role in the development of bone forming osteoblasts and bone remodeling. This study analyzed Wnt‐10b control of gene expression throughout osteoblast differentiation. Genes regulated by Wnt‐10b were identified by analyzing five mouse osteoblast lines (C3H10T1/2, ST‐2, bone marrow stromal cells, MC‐3T3, and calvarial osteoblasts). These cell lines were exposed to media from a Wnt‐10b producing cell line via a transwell system. mRNA levels of 32 osteoblastic, Wnt and BMP responsive genes were quantified by qPCR. Several genes were consistently up/down regulated, representing different stages of osteoblast commitment and differentiation. In the second part of the study, C3H10T1/2 cells were treated with BMP2 osteoblast differentiation media to stimulate the growth of osteoblastic cells. The control and Wnt‐10b treated cells were harvested at 0, 6, 9, 12, or 15 days to observe the effect of Wnt‐10b during differentiation. Analysis of 64 genes showed two known Wnt‐3a targets, complement component 3 (C3) and chemokine ligand 16 (Cxcl16), were highly regulated by Wnt‐10b. This study indentifies a number of important genes that are regulated by Wnt‐10b during osteoblast differentiation. This project was funded by the Mayo Graduate School and the Summer Undergraduate Research Fellowship.
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers
Amin, Mahul B. , Epstein, Jonathan I. , Hansel, Donna E. , Paner, Gladell P. , True, Larry, Bayder, Dilek, Bivalacqua, Trinity J. , Brimo, Fadi , Cheng, Liang , Cheville, John C. , Dalbagni, Guido , Falzarano, Sara M. , Gordetsky, Jennifer , Gupta, Sounak , Hes, Ondřej , Kaushal, Seema , Kunju, Lakshmi P., McKenney, Jesse K. , Netto, George J. , Osunkoya, Adeboye O. , Pan, Chin , Pivovarcikova, Kristina, Raspollini, Maria Rosaria , Reis, Henning , Trpkov, Kiril , Weyerer, Veronika , Zhou, Ming , Reuter, Victor, Cheng, Liang , Cheng, Liang , Gordetsky, Jennifer B , Trpkov, Kiril , Compérat, Éva , Al-Ahmadie, Hikmat A , Guo, Charles Chuanhai , Iyer, Gopa , Magi‐Galluzzi, Cristina , Matoso, Andres , Pan, Chin Chen, Rosenberg, Jonathan E , Rouprêt, Morgan , Shah, Rajal B. , Shariat, Shahrokh F.

Mayo Clinic

Advances in Anatomic Pathology | June 15, 2021 | Volume: 28 | Issue: 4 | Pages: 196-208

10.1097/pap.0000000000000309 | PMID 34128484 Get It

The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder cancer focusing on important topics of high interest for the practicing surgical pathologist and urologist. This review represents the second of 2 manuscripts ensuing from this effort. Herein, we address the effective reporting of bladder cancer, focusing particularly on newly published data since the last 2016 World Health Organization (WHO) classification. In addition, this review focuses on the importance of reporting bladder cancer with divergent differentiation and variant (subtypes of urothelial carcinoma) histologies and the potential impact on patient care. We provide new recommendations for reporting pT1 staging in diagnostic pathology. Furthermore, we explore molecular evolution and classification, emphasizing aspects that impact the understanding of important concepts relevant to reporting and management of patients.
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia
Amin, Mahul B. , Epstein, Jonathan I. , True, Lawrence D. , Hansel, Donna E. , Paner, Gladell P. , Baydar, Dilek Ertoy , Bivalacqua, Trinity J. , Brimo, Fadi , Cheng, Liang , Cheville, John C. , Dalbagni, Guido , Falzarano, Sara M. , Gordetsky, Jennifer , Gupta, Sounak , Hes, O., Kaushal, Seema , Kunju, Lakshmi P., Netto, George J. , Osunkoya, Adeboye O. , Pan, Chin , Pivovarcikova, Kristina, Raspollini, Maria Rosaria , Reis, Henning , Trpkov, Kiril , Weyerer, Veronika , Zhou, Ming , McKenney, Jesse K. , Reuter, Victor E. , Cheng, Liang , Cheng, Liang , Gordetsky, Jennifer B , Trpkov, Kiril , Compérat, Éva , Al-Ahmadie, Hikmat A , Guo, Charles Chuanhai , Iyer, Gopa , Magi‐Galluzzi, Cristina , Matoso, Andres , Pan, Chin Chen, Rosenberg, Jonathan E , Rouprêt, Morgan , Shah, Rajal B. , Shariat, Shahrokh F.

Mayo Clinic

Advances in Anatomic Pathology | June 15, 2021 | Volume: 28 | Issue: 4 | Pages: 179-195

10.1097/pap.0000000000000308 | PMID 34128483 Get It

The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder neoplasia with a focus on issues relevant to the practicing surgical pathologist for the understanding and effective reporting of bladder cancer, emphasizing particularly on the newly accumulated evidence post-2016 World Health Organization (WHO) classification. The work is presented in 2 manuscripts. Here, in the first, we revisit the nomenclature and classification system used for grading flat and papillary urothelial lesions centering on clinical relevance, and on dilemmas related to application in routine reporting. As patients of noninvasive bladder cancer frequently undergo cystoscopy and biopsy in their typically prolonged clinical course and for surveillance of disease, we discuss morphologies presented in these scenarios which may not have readily applicable diagnostic terms in the WHO classification. The topic of inverted patterns in urothelial neoplasia, particularly when prominent or exclusive, and beyond inverted papilloma has not been addressed formally in the WHO classification. Herein we provide a through review and suggest guidelines for when and how to report such lesions. In promulgating these GUPS recommendations, we aim to provide clarity on the clinical application of these not so uncommon diagnostically challenging situations encountered in routine practice, while also importantly advocating consistent terminology which would inform future work.
Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms
Almodallal, Yahya , Duong, Quyen, Satele, Daniel , Novotny, Paul J. , Cook, Kathryn , Chauhan, Cynthia, Daiss, Michelle K., Le‐Rademacher, Jennifer , Looker, Sherry, Martin, Nichole , Smestad, Michanda F., Mandrekar, Sumithra J. , Jatoi, Aminah , Novotny, Paul, Cook, Kathryn D , Mandrekar, Sumithra J , Jatoi, Aminah , Le-Rademacher, Jennifer G , Winham, Stacey J.

Mayo Clinic

JCO Oncology Practice | June 14, 2021 | Volume: 17 | Issue: 10 | Pages: e1460-e1472

10.1200/op.21.00071 | PMID 34125586 Get It

PURPOSE:This randomized, double-blind study sought to understand whether cancer clinical trial consent form verbosity detracts from patients' decision making on trial enrollment.METHODS:This trial tested mock consent forms of 2,000, 4,000, and 6,000 words. The first two comprised the two experimental arms and the third the control arm. Phase II was conducted to identify the promising arm, which, in phase III, was compared with the control arm. Each consent form described the same trial. Eligible adult patients reported a cancer history and English literacy. The primary end point used a patient-reported Likert scale to assess the relationship between information in the consent form and trial decision making.RESULTS:In phase II, 93 patients were accrued and prompted the selection of the 2,000-word consent form for phase III. In phase III, 182 patients were recruited, resulting in 240 total evaluable patients to compare the 2,000-word versus the 6,000-word arm (control). For the primary end point, 103 (84%) and 107 (91%) patients in the 2,000- and 6,000-word arms, respectively, strongly agreed or agreed with the following: “The information in this consent form helped me make a decision about whether or not to enroll in the trial” (two-sided, P = .14). Median time to read each consent form was 8 and 12 minutes, respectively (two-sided, P < .0001). Among those assigned these consent forms, 84% and 73%, respectively (two-sided, P = .04) signed or expressed a willingness to sign.CONCLUSION:This study's primary end point was not met. However, secondary outcomes suggest a need to further study the efficiency and efficacy of shorter consent forms for cancer clinical trial enrollment.
Early role for a Na + ,K + -ATPase ( ATP1A3 ) in brain development
Smith, Richard S. , Akula, Shyam K. , Neil, Jennifer E., Wang, Yidi , Hill, Robert , Goldman, Melissa , Mullally, Christopher D. , Reed, Nora , Bello‐Espinosa, Luis , Flores‐Sarnat, Laura , Monteiro, Fabíola Paoli , Casella, Erasmo Barbante , Barkovich, A. James , Gonzalez–Heydrich, Joseph , Florio, Marta , Akula, Shyam K , Wang, Yidi , Bello-Espinosa, Luis , Erasmo, Casella B , Vairo, Filippo , Barkovich, A James , Gonzalez-Heydrich, Joseph , Walsh, Christopher A , Hill, R. Sean, Vairo, Filippo Pinto e , Morava, Éva , Brownstein, Catherine A. , McCarroll, Steven A. , Walsh, Christopher A.

Mayo Clinic

Proceedings of the National Academy of Sciences | June 14, 2021 | Volume: 118 | Issue: 25 | Pages: No page available

10.1073/pnas.2023333118 | PMID 34161264 Get It

Significance By evaluating children with a malformed cerebral cortex, we identified an ATPase pump (ATP1A3) with an early role in brain development. The ATP1A3 pump maintains the physiological concentration of sodium and potassium ions in cells, a process critical for osmotic equilibrium and membrane potential across several developing cell populations. We employed single-cell sequencing approaches to identify key enrichments for ATP1A3 expression during human cortex development. Unravelling this early cell-type–specific pathophysiology in the developing brain offers a potential basis for the treatment of ATP1A3 -related diseases affecting prenatal and early childhood development.
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening
Requena, David , Ramos‐Espiritu, Lavoisier , Ng, Denise , Bhola, Patrick , Jong, Ype P. de , Wang, Ruisi , Narayan, Nicole J.C., Shebl, Bassem , Michailidis, Eleftherios , Vercauteren, Koen , Hurley, Arlene , Farber, Benjamin A. , Hammond, William J. , Saltsman, James A. , Weinberg, Ethan M. , Glickman, J. Fraser , Lyons, Barbara A. , Ellison, Jessica, Schadde, Erik , Hertl, Martin, Leiting, Jennifer L. , Truty, Mark J. , Smoot, Rory L. , Tierney, Faith, Kato, Tomoaki , Wendel, Hans‐Guido , Rice, Charles M. , Letai, Anthony , Simon, Sanford M. , Requena, David , de Jong, Ype P , Michailidis, Eleftherios , Vercauteren, Koen O A , Hurley, Arlene M , Farber, Benjamin A , Hammond, William J , Glickman, J Fraser , Leiting, Jennifer L , Smoot, Rory L , LaQuaglia, Michael P , Simon, Sanford M , Weinberg, Ethan M , Lalazar, Gadi , Levin, Solomon , Kabbani, Mohammad , LaQuaglia, Michael P. , Coffino, Philip , Torbenson, Michael , Ortiz, Michael V.

Mayo Clinic

Cancer Discovery | June 14, 2021 | Volume: 11 | Issue: 10 | Pages: 2544-2563

10.1158/2159-8290.cd-20-0872 | PMID 34127480 Get It

Abstract To repurpose therapeutics for fibrolamellar carcinoma (FLC), we developed and validated patient-derived xenografts (PDX) from surgical resections. Most agents used clinically and inhibitors of oncogenes overexpressed in FLC showed little efficacy on PDX. A high-throughput functional drug screen found primary and metastatic FLC were vulnerable to clinically available inhibitors of TOPO1 and HDAC and to napabucasin. Napabucasin's efficacy was mediated through reactive oxygen species and inhibition of translation initiation, and specific inhibition of eIF4A was effective. The sensitivity of each PDX line inversely correlated with expression of the antiapoptotic protein Bcl-xL, and inhibition of Bcl-xL synergized with other drugs. Screening directly on cells dissociated from patient resections validated these results. This demonstrates that a direct functional screen on patient tumors provides therapeutically informative data within a clinically useful time frame. Identifying these novel therapeutic targets and combination therapies is an urgent need, as effective therapeutics for FLC are currently unavailable. Significance: Therapeutics informed by genomics have not yielded effective therapies for FLC. A functional screen identified TOPO1, HDAC inhibitors, and napabucasin as efficacious and synergistic with inhibition of Bcl-xL. Validation on cells dissociated directly from patient tumors demonstrates the ability for functional precision medicine in a solid tumor. This article is highlighted in the In This Issue feature, p. 2355
L-Arginine reduces downstream vascular contractility after flow-diverting device deployment: A preliminary study in a rabbit model
Ayers-Ringler, Jennifer , Parameswaran, Praveen Kolumam, Khashim, Zenith , Dai, Daying , Ding, Yonghong , Kallmes, David F. , Kadirvel, Ramanathan , Kolumam Parameswaran, Praveen, Ding, Yong-Hong , Dai, Daying

Mayo Clinic

Interventional Neuroradiology | June 12, 2021 | Volume: 28 | Issue: 2 | Pages: 183-189

10.1177/15910199211025107 | PMID 34120493 Get It

Background Flow diverters (FDs) are an effective treatment for intracranial aneurysms, though not free from hemorrhagic complications. A previous study demonstrated increased vascular contractility after FD-implantation as a potential mechanism of distal complications. Our study aimed to investigate whether L-arginine medication affects vascular contractility following FD deployment in a rabbit model. Methods FDs were implanted in the aorta of normal rabbits (+FD, n = 10), with sham-operated aorta as controls (n = 5). L-Arginine was given in the drinking water (2.25% L-arginine hydrochloride) of half of the +FD animals (+FD/+Arg). Force contraction vascular contractility studies were performed on the aortic rings proximal and distal to the FD using an organ bath. Total eNOS, eNOS(pS1177), eNOS(pT495), COX-2, and S100A4 were quantified by western analysis on total protein lysates from aortic segments, normalizing to GAPDH. Results Mean vascular contractility was 53% higher in distal relative to proximal aortic segments (P = 0.0038) in +FD animals, but were not significantly different in +FD/+Arg animals, or in sham-operated controls. The +FD animals expressed significantly reduced levels of eNOS(pS1177) than sham-operated controls (P = 0.0335), while both the +FD and +FD/+Arg groups had reduced levels of eNOS(pT495) relative to sham-operated controls (P = 0.0331 and P = 0.0311, respectively). Conclusion These results suggest that L-arginine medication reduces distal vascular contractility after FD treatment via nitric oxide production and thus might mitigate risk for downstream complications.
Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial
Kudva, Yogish C. , Laffel, Lori M. , Brown, Sue A. , Raghinaru, Dan, Pinsker, Jordan E. , Ekhlaspour, Laya , Messer, Laurel H. , Kovatchev, Boris , Lum, John W. , Gonder‐Frederick, Linda , Anderson, Stacey M. , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David W. , O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Forlenza, Gregory P. , Alonso, G. Todd, Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Buckingham, Bruce A. , Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Kollman, Craig, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Eggerman, Thomas L., Messer, Laurel H , Lum, John , Forlenza, Gregory P , Kovatchev, Boris , Buckingham, Bruce , Levy, Carol J. , Beck, Roy W. , Oliveri, Mary Clancy , Isganaitis, Elvira , Kumari, Kanchan, Wadwa, R Paul , Doyle, Francis J. , Kollman, Craig , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | June 11, 2021 | Volume: 23 | Issue: 10 | Pages: 673-683

10.1089/dia.2021.0089 | PMID 34115959 Get It

Background: Closed-loop control (CLC) has been shown to improve glucose time in range and other glucose metrics; however, randomized trials >3 months comparing CLC with sensor-augmented pump (SAP) therapy are limited. We recently reported glucose control outcomes from the 6-month international Diabetes Closed-Loop (iDCL) trial; we now report patient-reported outcomes (PROs) in this iDCL trial. Methods: Participants were randomized 2:1 to CLC ( N = 112) versus SAP ( N = 56) and completed questionnaires, including Hypoglycemia Fear Survey, Diabetes Distress Scale (DDS), Hypoglycemia Awareness, Hypoglycemia Confidence, Hyperglycemia Avoidance, and Positive Expectancies of CLC (INSPIRE) at baseline, 3, and 6 months. CLC participants also completed Diabetes Technology Expectations and Acceptance and System Usability Scale (SUS). Results: The Hypoglycemia Fear Survey Behavior subscale improved significantly after 6 months of CLC compared with SAP. DDS did not differ except for powerless subscale scores, which worsened at 3 months in SAP. Whereas Hypoglycemia Awareness and Hyperglycemia Avoidance did not differ between groups, CLC participants showed a tendency toward improved confidence in managing hypoglycemia. The INSPIRE questionnaire showed favorable scores in the CLC group for teens and parents, with a similar trend for adults. At baseline and 6 months, CLC participants had high positive expectations for the device with Diabetes Technology Acceptance and SUS showing high benefit and low burden scores. Conclusion: CLC improved some PROs compared with SAP. Participants reported high benefit and low burden with CLC. Clinical Trial Identifier: NCT03563313.
Return to Sports After Primary Reverse Shoulder Arthroplasty: Outcomes at Mean 4-Year Follow-up
Mara, Kristin C. , Tangtiphaiboontana, Jennifer , Jensen, Andrew R, Sanchez-Sotelo, Joaquin, Mara, Kristin C , Jensen, Andrew R. , Camp, Christopher L. , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 10, 2021 | Volume: 9 | Issue: 6 | Pages: No page available

10.1177/23259671211012393 | PMID 34179208 Get It

Background: With the expanding use of reverse shoulder arthroplasty (RSA) to treat various shoulder conditions, there has been a rise in the number of RSAs performed, especially in physically active patients. Limited information regarding sports after RSA is available to properly counsel patients on postoperative expectations. Purpose: To assess the rate of return to sports as well as the ability to return to the same level of preoperative intensity, frequency, and duration of sport after primary RSA. Study Design: Case series; Level of evidence, 4. Methods: This was a retrospective review of patients who underwent primary RSA at our institution between 2014 and 2016. Shoulder motion, Subjective Shoulder Value score, American Shoulder and Elbow Surgeons score, pre- and postoperative sports activities, and barriers to return to sport were assessed in 109 patients after RSA (93 patients with unilateral RSA and 16 patients with bilateral RSA). The mean age at the time of surgery was 70 years (range, 34-86 years), with a mean follow-up of 3.9 years (range, 2-12 years). Results: The mean rate of return to sports was 70.1% (range, 0%-100%). There was no difference in return to sports between those with uni- and bilateral RSA ( P = .64). Fishing, swimming, elliptical/treadmill, and hunting were the most common sports after RSA with return rates of 91%, 73%, 86%, and 82% respectively. A majority of patients returned to the same level of preoperative intensity, frequency, and duration for all sports except for climbing and swimming. There was a lower mean rate of return for high-demand sports (62.9%) compared with low- and medium-demand sports (76.7%) ( P = .005). The most common reasons for inability to return to sports included limited motion, fear of injury, and weakness. Conclusion: Patients who had undergone primary uni- or bilateral RSA reported a 70.1% rate of return to sports with maintenance of the same level of intensity, duration, and frequency of preoperative sport participation. Rates of return to high-demand sports were lower than low- and medium-demand sports. Patients also had difficulty returning to overhead sports.
Sex Differences in the Effect of Acute Intermittent Hypoxia on Respiratory‐Sympathetic Coupling in Humans
Ivie, Clayton L., Edmunds, Jane, Ott, Elizabeth P., Jacob, Dain W. , Baker, Sarah , Acevedo, Camila Margarita Manrique, Limberg, Jacqueline K. , Harper, Jennifer L.

Mayo Clinic

The FASEB Journal | June 10, 2021 | Volume: 35 | Issue: S1 | Pages: No page available

10.1096/fasebj.2021.35.s1.01494 Get It

Background Sex‐related differences in respiratory‐sympathetic coupling have been described in preclinical models of intermittent hypoxia (IH) and have been implicated in the development of neurogenic hypertension. Based on sex disparities in the respiratory and blood pressure response to acute IH in humans as well as changes in respiratory‐sympathetic coupling in clinical sleep apnea, we examined sex‐related differences in respiratory modulation of muscle sympathetic nerve activity (MSNA) following acute IH in healthy humans. We hypothesized the magnitude of respiratory‐sympathetic coupling would increase in both men and women following IH; however, the respiratory patterning of MSNA following IH would be sex‐specific. Methods Heart rate, MSNA, and respiration were assessed in 21 healthy young men (30±1 yrs) and 10 healthy young women (28±1 yrs) during normoxic rest prior to and following IH. IH was achieved by alternating between a hypercapnic hypoxic (3% carbon dioxide, 5% oxygen) gas cylinder and room air (21% oxygen) to target 15 hypoxic events over 30‐min. Respiratory modulation of MSNA was assessed by fitting polynomials to cross‐correlation histograms constructed between sympathetic spikes and respiration. Results MSNA was elevated following IH in both men (34±2 to 41±3 bursts/100 heart beats) and women (30±4 to 35±5 bursts/100 heart beats) (p<0.01). When examining the normalized temporal profile of MSNA, both men and women exhibited changes in respiratory patterning of MSNA following IH; however, the pattern of MSNA differed by sex. Following IH, women exhibited more sympathetic activity during late expiration and less during post‐inspiration (interaction of IH and time, p<0.01). In contrast, men exhibited greater sympathetic activity during post‐inspiration following IH (interaction of IH and time, p<0.01). Conclusions Both men and women exhibit changes in respiratory patterning of MSNA following acute IH; however, this pattern differs by sex. These data support sex disparities in respiratory‐sympathetic coupling and advance our understanding of sex‐specific changes in sympathetic activation following IH which may have important implications for the development of neurogenic hypertension.